Trial Profile
An Open-label, Parallel Group, Randomized, Two-sequence, Three-way Crossover Study to Assess the Relative Bioavailability of Solifenacin Succinate and Mirabegron Fixed-dose Combination Tablets Compared to Co-administration of Single Entity Tablets at Three Dose Strengths in Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2014
Price :
$35
*
At a glance
- Drugs Mirabegron+solifenacin (Primary) ; Mirabegron; Solifenacin
- Indications Overactive bladder; Urinary incontinence
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Europe Ltd
- 17 Dec 2013 New trial record